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The Spanish Rare Diseases Registries Research Network
(SpainRDR) is a project aimed to build the National Rare
Diseases Registry in Spain based on the input of two diff-
erent methods: patient outcome research registries and
population-based registries. The project has been
approved within the IRDiRC framework and is co-funded
by the Institute of Health Carlos III (ISCIII), the Health
Departments of the Autonomous Communities (regions)
and the Spanish Ministry of Health, Social Services and
Equity (MSSSI) of Spain. The project addresses one of the
main recommendations of the National Rare Diseases
Strategy and also collaborates with some other RD regis-
tering actions like GRDR-NIH, RD-CONNECT and
EPIRARE.
With the unprecedented collaboration and support of
medical societies, researcher networks, patient organiza-
tions, pharma industry and health policy makers,
SpainRDR is running an effective and necessary way to
develop knowledge and raise awareness of the rare dis-
eases burden, which will contribute to design the provision
of health and social services as well as the improvement of
diagnosis, prognosis, treatment and quality life of patients
and families affected by RD.
The project is leading by the Institute of Rare Diseases
research (IIER, ISCIII) and it is organised in six work
packages: WP1 Coordination and Management, WP2
Registering activity related methods, WP3 Data analysis
and outcomes research, WP4 Quality Assessment and
ELSI issues, WP5 Dissemination and impact, and WP6
Patient registries.
A Manual of Procedures including a quality assurance
plan, common data elements, coding and classifications
criteria, standard operating procedures, ELSI rules,
statistical analysis methods and the official website net-
work are actions already carried out or being finalized.
Specific CDE have been also consolidated for those
patient registries already implemented at the central RDR
repository (alpha-1 antitrypsin deficiency, pulmonary his-
tiocytosis, lymphangiomyomatosis, alveolar proteinosis,
sarcoidosis, thraqueal stenosis, Sexual Developmental
Disorders, Bullous Epidermolysis, ataxias and familiar
spastic paraparesis). At the same time, some other patient
registries’ CDE´s are currently being developed, such as
Congenital Suprarenal Hyperplasia and Bradykinin
linked angioedema. We are preparing also CDEs for
cystinosis and congenital anaemia.
After the necessary pilot study developed during 2013,
we are now collecting prevalence cases from 2012-2012
and the first preliminary results are already available
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